The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Mild Innate Immune Activation Overrides Efficient Nanoparticle‐Mediated RNA Delivery
Open accessAbstract
Clinical mRNA delivery remains challenging, in large part because how physiology alters delivery in vivo remains underexplored. For example, mRNA delivered by lipid nanoparticles (LNPs) is being considered to treat inflammation, but whether inflammation itself changes delivery remains understudied. Relationships between immunity, endocytosis, and mRNA translation lead to hypothesize that toll‐like receptor 4 (TLR4) activation reduced LNP‐mediated mRNA delivery. Therefore, LNP uptake, endosomal escape, and mRNA translation with and without TLR4 activation are quantified. In vivo DNA barcoding is used to discover a novel LNP that delivers mRNA to Kupffer cells at clinical doses; unlike most LNPs, this LNP does not preferentially target hepatocytes. TLR4 activation blocks mRNA translation in all tested cell types, without reducing LNP uptake; inhibiting TLR4 or its downstream effector protein kinase R improved delivery. The discrepant effects of TLR4 on i) LNP uptake and ii) translation suggests TLR4 activation can “override” LNP targeting, even after mRNA is delivered into target cells. Given near‐future clinical trials using mRNA to modulate inflammation, this highlights the need to understand inflammatory signaling in on‐ and off‐target cells. More generally, this suggests an LNP which delivers mRNA to one inflammatory disease may not deliver mRNA to another.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, immune responses to IVT mRNA may also suppress antigen expression and negatively affect vaccine efficacy175,180,181.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [175]
In the citing paper
“Although the immunogenicity of these lipids has not yet been fully understood, complement system and Toll-like receptors may participate in innate immune activation170,173–175.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [175]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology
Tenzer, S., Docter, D., Kuharev, J., Musyanovych, A., Fetz, V., Hecht, R., Schlenk, F., Fischer, D., Kiouptsi, K., Reinhardt, C., et al. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2013.181 · Cited by 2,283
Salvati, A., Pitek, A. S., Monopoli, M. P., Prapainop, K., Bombelli, F. B., Hristov, D. R., Kelly, P. M., Åberg, C., Mahon, E., & Dawson, K. A. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2012.237 · Cited by 1,912
Walkey, C. D., & Chan, W. C. W. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15233e · Cited by 1,758
Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-β
Kagan, J. C., Su, T., Horng, T., Chow, A. Y., Akira, S., & Medzhitov, R. M. (2008) · Nature Immunology · doi:10.1038/ni1569 · Cited by 1,310
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Physical Principles of Nanoparticle Cellular Endocytosis
Zhang, S., Gao, H., & Bao, G. (2015) · ACS Nano · doi:10.1021/acsnano.5b03184 · Cited by 1,103
Cited by
Sorted by citations
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Self-citationLipids and Lipid Derivatives for RNA Delivery
Zhang, Y., Sun, C., Wang, C., Jankovic, K. E., & Dong, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00244 · Cited by 649
Lipid nanoparticles for nucleic acid delivery: Current perspectives
Samaridou, E., Heyes, J. A., & Lutwyche, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.002 · Cited by 609
The landscape of mRNA nanomedicine
Huang, X., Kong, N., Zhang, X., Cao, Y., Langer, R., & Tao, W. (2022) · Nature Medicine · doi:10.1038/s41591-022-02061-1 · Cited by 511
Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs
Lokugamage, M. P., Vanover, D. A., Beyersdorf, J. P., Hatit, M. Z. C., Rotolo, L., Echeverri, E. S., Peck, H. E., Ni, H., Yoon, J., Kim, Y., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00786-x · Cited by 539
Self-citationmRNA vaccine: a potential therapeutic strategy
Wang, Y., Zhang, Z., Luo, J., Han, X., Wei, Y., & Wei, X. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01311-z · Cited by 422
LoPresti, S. T., Arral, M. L., Chaudhary, N., & Whitehead, K. A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.046 · Cited by 293
Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy
You, Y., Tian, Y., Yang, Z., Shi, J., Kwak, K. J., Tong, Y., Estania, A. P., Cao, J., Hsu, W.-H., Liu, Y., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00989-w · Cited by 258
Strategies to reduce the risks of mRNA drug and vaccine toxicity
Bitounis, D., Jacquinet, E., Rogers, M. A., & Amiji, M. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00859-3 · Cited by 242
Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo
Ni, H., Hatit, M. Z. C., Zhao, K., Loughrey, D., Lokugamage, M. P., Peck, H. E., Cid, A. D., Muralidharan, A., Kim, Y., Santangelo, P. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32281-5 · Cited by 202
Self-citationFunctionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing
Zhang, X., Zhao, W., Nguyen, G. N., Zhang, C., Zeng, C., Yan, J., Du, S., Hou, X., Li, W., Jiang, J., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc2315 · Cited by 184
Loughrey, D., & Dahlman, J. E. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00601 · Cited by 173
Self-citationSzebeni, J., Storm, G., Ljubimova, J. Y., Castells, M., Phillips, E. J., Turjeman, K., Barenholz, Y., Crommelin, D. J. A., & Dobrovolskaia, M. A. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01071-x · Cited by 170
Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE)
Parhiz, H., Brenner, J. S., Patel, P., Papp, T. E., Shahnawaz, H., Li, Q., Shi, R., Zamora, M. E., Yadegari, A., Marcos-Contreras, O. A., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.027 · Cited by 151
Species-dependent in vivo mRNA delivery and cellular responses to nanoparticles
Hatit, M. Z. C., Lokugamage, M. P., Dobrowolski, C. N., Paunovska, K., Ni, H., Zhao, K., Vanover, D. A., Beyersdorf, J. P., Peck, H. E., Loughrey, D., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-021-01030-y · Cited by 158
Self-citationThe use of RNA-based treatments in the field of cancer immunotherapy
Chehelgerdi, M., & Chehelgerdi, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01807-w · Cited by 149
Ben‐Akiva, E., Karlsson, J. E., Hemmati, S., Yu, H., Tzeng, S. Y., Pardoll, D. M., & Green, J. J. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2301606120 · Cited by 145
Physiological Barriers and Strategies of Lipid‐Based Nanoparticles for Nucleic Acid Drug Delivery
Hu, M., Li, X., You, Z., Cai, R., & Chen, C. (2023) · Advanced Materials · doi:10.1002/adma.202303266 · Cited by 142
Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies
Wei, P.-S., Thota, N., John, G., Chang, E., Lee, S., Wang, Y., Ma, Z., Tsai, Y.-H., & Mei, K. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.030 · Cited by 138
From structural design to delivery: mRNA therapeutics for cancer immunotherapy
Zhou, F., Huang, L., Li, S., Yang, W., Chen, F., Cai, Z., Liu, X., Xu, W., Lehto, V., Lächelt, U., et al. (2023) · Exploration · doi:10.1002/exp.20210146 · Cited by 117
Ly, H. H., Daniel, S., Soriano, S. K. V., Kis, Z., & Blakney, A. K. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00032 · Cited by 120
mRNA vaccines for COVID-19 and diverse diseases
Hussain, A., Yang, H., Zhang, M., Liu, Q., Alotaibi, G., Irfan, M. F., He, H., Chang, J. K., Liang, X., Weng, Y., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.032 · Cited by 121
Wu, L., Li, X., Qian, X., Wang, S., Liu, J., & Yan, J. (2024) · Vaccines · doi:10.3390/vaccines12020186 · Cited by 137
Ye, Z., Chen, J., Zhao, X., Li, Y., Harmon, J., Huang, C., Chen, J., & Xu, Q. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c01532 · Cited by 110
Mukai, H., Ogawa, K., Kato, N., & Kawakami, S. (2022) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2022.100450 · Cited by 108
Dobrowolski, C. N., Paunovska, K., Echeverri, E. S., Loughrey, D., Sanchez, A. J. D. S., Ni, H., Hatit, M. Z. C., Lokugamage, M. P., Kuzminich, Y., Peck, H. E., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01146-9 · Cited by 113
Self-citationmRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients
Bidram, M., Zhao, Y., Shebardina, N. G., Baldin, A. V., Bazhin, A. V., Ganjalikhany, M. R., Zamyatnin, A. A., & Ganjalıkhani-Hakemi, M. (2021) · Vaccines · doi:10.3390/vaccines9101060 · Cited by 111
Chen, K., Fan, N., Huang, H., Jiang, X., Qin, S., Xiao, W., Zheng, Q., Zhang, Y., Duan, X., Qin, Z., et al. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202204692 · Cited by 104
Soroudi, S., Jaafari, M. R., & Arabi, L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.023 · Cited by 96
Ripoll, M., Bernard, M., Vaure, C., Bazin, E., Commandeur, S., Perkov, V., Lemdani, K., Nicolaï, M., Bonifassi, P., Kichler, A., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121570 · Cited by 89
Ralvenius, W. T., Andresen, J. L., Huston, M. M., Penney, J., Bonner, J. M., Fenton, O. S., Langer, R., & Tsai, L. (2024) · Advanced Materials · doi:10.1002/adma.202309225 · Cited by 78
Gan, Z., Lokugamage, M. P., Hatit, M. Z. C., Loughrey, D., Paunovska, K., Sato, M., Cristian, A., & Dahlman, J. E. (2020) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10161 · Cited by 75
Self-citationCao, Y., He, Z., Chen, Q., He, X., Su, L., Yu, W., Zhang, M., Yang, H., Huang, X., & Li, J. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c01784 · Cited by 73
Paunovska, K., Sanchez, A. J. D. S., Lokugamage, M. P., Loughrey, D., Echeverri, E. S., Cristian, A., Hatit, M. Z. C., Santangelo, P. J., Zhao, K., & Dahlman, J. E. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c03741 · Cited by 78
Self-citationWalther, J., Porenta, D., Wilbie, D., Seinen, C. W., Benne, N., Yang, Q., de Jong, O. G., Lei, Z., & Mastrobattista, E. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114207 · Cited by 80
The Transcriptional Response to Lung-Targeting Lipid Nanoparticles in Vivo
Radmand, A., Lokugamage, M. P., Kim, H., Dobrowolski, C. N., Zenhausern, R., Loughrey, D., Huayamares, S. G., Hatit, M. Z. C., Ni, H., Cid, A. D., et al. (2023) · Nano Letters · doi:10.1021/acs.nanolett.2c04479 · Cited by 77
Self-citationNanoparticle stereochemistry-dependent endocytic processing improves in vivo mRNA delivery
Hatit, M. Z. C., Dobrowolski, C. N., Lokugamage, M. P., Loughrey, D., Ni, H., Zurla, C., Sanchez, A. J. D. S., Radmand, A., Huayamares, S. G., Zenhausern, R., et al. (2023) · Nature Chemistry · doi:10.1038/s41557-023-01138-9 · Cited by 71
Self-citationIonizable Lipid Nanoparticles for mRNA Delivery
Tang, X., Zhang, Y., & Han, X. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202300006 · Cited by 76
Treating Cystic Fibrosis with mRNA and CRISPR
Sanchez, A. D. S., Paunovska, K., Cristian, A., & Dahlman, J. E. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.137 · Cited by 75
Self-citationTherapeutic RNA Delivery for COVID and Other Diseases
Dobrowolski, C. N., Paunovska, K., Hatit, M. Z. C., Lokugamage, M. P., & Dahlman, J. E. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002022 · Cited by 62
Self-citationDelivery of mRNA for regulating functions of immune cells
Shi, J. Y., Huang, M., Lu, Z.-D., Du, X., Shen, S., Xu, C., & Wang, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.033 · Cited by 62
Yang, J., Duan, S., Ye, H., Ge, C., Piao, C., Chen, Y., Lee, M., & Yin, L. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202008960 · Cited by 62
Korzun, T., Moses, A. S., Jozić, A., Grigoriev, V., Newton, S., Kim, J., Diba, P., Sattler, A. L., Levasseur, P. R., Le, N., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c05088 · Cited by 64
DeFrancesco, L. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0697-7 · Cited by 55
Tian, Y. P., Tirrell, M., & LaBelle, J. L. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202102600 · Cited by 53
Targeting strategies for mRNA delivery
Meyer, R. A., Neshat, S. Y., Green, J. J., Santos, J. L., & Tuesca, A. D. (2022) · Materials Today Advances · doi:10.1016/j.mtadv.2022.100240 · Cited by 55
Substituting racemic ionizable lipids with stereopure ionizable lipids can increase mRNA delivery
Sanchez, A. J. D. S., Zhao, K., Huayamares, S. G., Hatit, M. Z. C., Lokugamage, M. P., Loughrey, D., Dobrowolski, C. N., Wang, S., Kim, H., Paunovska, K., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.037 · Cited by 53
Self-citationEmerging Concepts of Nanobiotechnology in mRNA Delivery
Wang, Y., & Yu, C. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202003545 · Cited by 54
Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics
de Vyver, T. V., Smedt, S. C. D., & Raemdonck, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114041 · Cited by 51
Cellular Trafficking of Nanotechnology‐Mediated mRNA Delivery
Huang, P., Deng, H., Wang, C., Zhou, Y., & Chen, X. S. (2023) · Advanced Materials · doi:10.1002/adma.202307822 · Cited by 53
Kubara, K., Yamazaki, K., Miyazaki, T., Kondo, K., Kurotaki, D., Tamura, T., & Suzuki, Y. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.020 · Cited by 51
Advanced Nanomaterials for Preparedness Against (Re‐)Emerging Viral Diseases
Kim, E., Lim, E., Park, G., Park, C., Lim, J., Lee, H. J., Na, W., Yeom, M., Kim, J., Song, D., et al. (2021) · Advanced Materials · doi:10.1002/adma.202005927 · Cited by 47
On the mechanism of tissue-selective gene delivery by lipid nanoparticles
Kimura, S., & Harashima, H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.03.052 · Cited by 46
Efficient Delivery of mRNA Using Crosslinked Nucleic Acid Nanogel as a Carrier
Huang, X., Zheng, R., Ding, F., Yang, J., Xie, M., Liu, X., Li, J., Feng, J. C., Zhu, X., & Zhang, C. (2020) · ACS Materials Letters · doi:10.1021/acsmaterialslett.0c00375 · Cited by 44
Dendritic Cell‐Mimicking Nanoparticles Promote mRNA Delivery to Lymphoid Organs
Cao, Y., Long, J., Sun, H., Miao, Y., Sang, Y., Lü, H., Yu, C., Zhang, Z., Wang, L., Yang, J., et al. (2023) · Advanced Science · doi:10.1002/advs.202302423 · Cited by 41
Ushering in the era of tRNA medicines
Anastassiadis, T., & Köhrer, C. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105246 · Cited by 38
Qin, Z., Bouteau, A., Herbst, C., & Igyártó, B. Z. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010830 · Cited by 51
Korzun, T., Moses, A. S., Diba, P., Sattler, A. L., Taratula, O. R., Sahay, G., Taratula, O., & Marks, D. L. (2023) · Pharmaceuticals · doi:10.3390/ph16081088 · Cited by 40
Liang, Y., Zhang, J., Xu, C., Wang, J., Han, W., Yang, J., Wu, S., An, J., Liu, J., Zhang, Z., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c04116 · Cited by 36
A Polymeric Nanoparticle Formulation for Targeted mRNA Delivery to Fibroblasts
Rodrigues, A. F., Rebelo, C., Simões, S. M. N., Paulo, C., Pinho, S. L. C., Francisco, V., & Ferreira, L. (2022) · Advanced Science · doi:10.1002/advs.202205475 · Cited by 33
Chen, Z., Kelly, K., Cheng, H., Dong, X., Hedger, A. K., Li, L., Sontheimer, E. J., & Watts, J. K. (2023) · GEN Biotechnology · doi:10.1089/genbio.2023.0045 · Cited by 37
Perez‐Potti, A., Rodríguez-Pérez, M., Polo, E., Pelaz, B., & del Pino, P. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114829 · Cited by 38
Meany, E. L., Klich, J. H., Jons, C. K., Mao, T., Chaudhary, N., Utz, A., Baillet, J., Song, Y. E., Saouaf, O. M., Ou, B. S., et al. (2025) · Science Advances · doi:10.1126/sciadv.adr2631 · Cited by 37
Li, Y., Liu, L., Ji, W., Peng, H., Zhao, R., & Zhang, X. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101006 · Cited by 34
RNA Nanomedicine: Delivery Strategies and Applications
Byun, J., Wu, Y., Park, J.-W., Kim, J. S., Li, Q., Choi, J., Shin, N., Lan, M., Cai, Y., Lee, J., et al. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00860-z · Cited by 32
Cao, D., Zhu, J., Guo, Y., Zhou, Y., Zeng, J., Tu, Y., Zhao, Z., Xie, L., Song, E., Zhu, M., et al. (2025) · Science Advances · doi:10.1126/sciadv.adj0006 · Cited by 31
Nucleic acid delivery and nanoparticle design for COVID vaccines
Andresen, J. L., & Fenton, O. S. (2021) · MRS Bulletin · doi:10.1557/s43577-021-00169-2 · Cited by 32
Poly (beta‐amino ester) as an in vivo nanocarrier for therapeutic nucleic acids
Nezhad, M. S. (2022) · Biotechnology and Bioengineering · doi:10.1002/bit.28269 · Cited by 28
Elwakil, M. M. A., Suzuki, R., Khalifa, A. M., Elshami, R. M., Isono, T., Elewa, Y. H. A., Sato, Y., Nakamura, T., Satoh, T., & Harashima, H. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202303795 · Cited by 30
Increased PIP3 activity blocks nanoparticle mRNA delivery
Paunovska, K., Sanchez, A. D. S., Foster, M. T., Loughrey, D., Blanchard, E. L., Islam, F. Z., Gan, Z., Mantalaris, A., Santangelo, P. J., & Dahlman, J. E. (2020) · Science Advances · doi:10.1126/sciadv.aba5672 · Cited by 26
Self-citationGuo, Z., Zeng, C., Shen, Y., Hu, L., Zhang, H., Li, Z., Dong, W. X., Wang, Q., Liu, Q., Wang, Y., et al. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c01458 · Cited by 26
mRNA-delivery of IDO1 suppresses T cell-mediated autoimmunity
Kenney, L. L., Chiu, R. S.-Y., Dutra, M. N., Wactor, A., Honan, C., Shelerud, L. M., Corrigan, J. J., Yu, K. J., Ferrari, J. D., Jeffrey, K. L., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101717 · Cited by 28
Lipid nanoparticles technology in vaccines: Shaping the future of prophylactic medicine
Abdellatif, A. A. H., Younis, M. A., Alsowinea, A. F., Abdallah, E. M., Abdel‐Bakky, M. S., Al-Subaiyel, A., Hassan, Y. A., & Tawfeek, H. M. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.113111 · Cited by 24
Jin, C., Zhang, Y., Li, B., Gao, T., Wang, B., & Hua, P. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101136 · Cited by 19
Donahue, D. A., Ballesteros, C., Maruggi, G., Glover, C., Ringenberg, M. A., Marquis, M., Abdeljelil, N. B., Ashraf, A., Rodriguez, L.-A., & Stokes, A. H. (2022) · International Journal of Toxicology · doi:10.1177/10915818221138781 · Cited by 17
Costa, B., Boueri, B., Oliveira, C. L., Silveira, I., & Ribeiro, A. J. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2075846 · Cited by 17
Regulatory circular RNAs in viral diseases: applications in diagnosis and therapy
Wang, W. J., Sun, L., Huang, M.-T., Quan, Y., Jiang, T., Miao, Z., & Zhang, Q. (2023) · RNA Biology · doi:10.1080/15476286.2023.2272118 · Cited by 16
Golden Threads of Lipid Nanoparticles (LNPs) contributing to COVID-19 mRNA Vaccine: A Review
Vasu, M., Yadav, P., Satyanarayana, Y., Ahlawat, J., Dulla, S., & Kumar, K. N. (2024) · BioNanoScience · doi:10.1007/s12668-024-01589-5 · Cited by 16
Qin, Z., Bouteau, A., Herbst, C., & Igyártó, B. Z. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.16.484616 · Cited by 15
Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review
Belay, W. Y., Nibret, G., & Aschale, Y. (2023) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s418314 · Cited by 16
Advances and Strategies in Enhancing mRNA Cancer Vaccines
Zhang, M., Chen, S., Hu, H.-J., Ong, Y., & Ni, Q. (2025) · Advanced Materials · doi:10.1002/adma.202509880 · Cited by 17
Eş, İ., Thakur, A., Khaneghah, A. M., Foged, C., & de la Torre, L. G. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108342 · Cited by 13
du Preez, H. N., Lin, J., Maguire, G. E. M., Aldous, C. M., & Kruger, H. G. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14296 · Cited by 12
Kim, Y., Park, W., Kim, S., Kim, E. H., Choi, J., Jang, H., Ryu, Y., Hwang, J., Kim, M., Cho, Y. J., et al. (2026) · ACS Nano · doi:10.1021/acsnano.5c20535 · Cited by 12
Aderinto, N., Muili, A. O., Olatunji, G. D., Edun, M. T., & Aboderin, G. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001118 · Cited by 9
Current Perspectives and Future Prospects of mRNA Vaccines against Viral Diseases: A Brief Review.
Vasavi, K., Poloju, D., Puvvala, B., Madineni, K., Balaji, S. N., Sheela, C. M. P., Manchikanti, S. S. C., & Moon, S. M. (2022) · PubMed Central · doi:10.22088/ijmcm.bums.11.3.260 · Cited by 12
mRNA—From COVID-19 Treatment to Cancer Immunotherapy
Kŕause, W. (2023) · Biomedicines · doi:10.3390/biomedicines11020308 · Cited by 8
Kimura, S., & Harashima, H. (2024) · BioDrugs · doi:10.1007/s40259-024-00647-4 · Cited by 8
Martin, S., McConnell, R. E., Harrison, R. A., Jang, S. C., Sia, C. L., Kamerkar, S., Duboff, A. G., Jacob, L. M., Finn, J. D., & Estes, S. D. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28401 · Cited by 6
Han, Y., Wang, Y., Gao, X., Lei, Y., Li, Y., & Tang, Z. (2026) · Cancer Nexus · doi:10.1002/cnx2.70021 · Cited by 8
Recent strategies for enhanced delivery of mRNA to the lungs
Heiser, B. J., Veyssi, A., & Ghosh, D. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2485669 · Cited by 7
The rise of mRNA therapeutic vaccines
Du, J., Fan, Z., Huang, J., Li, Z., Hu, H., & Li, Y. (2025) · RSC Pharmaceutics · doi:10.1039/d4pm00309h · Cited by 5
Design of messenger RNA vaccines based on lipid-polymer hybrid nanoparticles
Baghel, S. S., Lokras, A. G., Dias, B. A., Landry, M. R., Cérda, S. L., Wadhwa, A., Herrera‐Barrera, M., Thakur, A., Rades, T., Franzyk, H., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114385 · Cited by 7
Tumor agnostic drug delivery with dynamic nanohydrogels
Housley, S. N., Bourque, A. R., Matyunina, L. V., Panicker, I., Echeverri, E. S., Izykowicz, M. M., Herrmann, O. A., Lee, S., Arboleda, J. C., Jamali, V., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-66788-4 · Cited by 5
Self-citationDecoding Undesirable Inflammatory Responses of Nucleic Acid‐Delivering Lipid Nanoparticles
Hu, R., Dou, Y., Li, C., Mu, Y., Ouyang, H., Shen, W., & Zhang, J. (2026) · Advanced Science · doi:10.1002/advs.75548 · Cited by 5
Lokras, A. G., Baghel, S. S., Jensen, R. F., Thakur, A., Franzyk, H., Thofte, O., Herrera‐Barrera, M., Landry, M. R., Ongun, M., Tami, A., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202505627 · Cited by 5
Moderne Konzepte der Nanobiotechnologie für mRNA‐Abgabesysteme
Wang, Y., & Yu, C. (2020) · Angewandte Chemie · doi:10.1002/ange.202003545 · Cited by 4
Engineered protein circuits for cancer therapyPreprint
Lu, A. C., Moeller, L., Moore, S., Ho, K., Tobin, V., Qiang, A., Zhang, E., Li, Z., Wang, M., Xia, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.16.647665 · Cited by 5
Walters, A. A., Hanafy, B. I., Lu, C., Marelli, S., Zam, A., Liu, K., Foreman, R. E., Soundararajan, R., Collin, P., Lindfors, L., et al. (2026) · Small · doi:10.1002/smll.74283 · Cited by 3
Metadata
- Authors
- Lokugamage, M. P., Gan, Z., Zurla, C., Levin, J., Islam, F. Z., Kalathoor, S., Sato, M., Sago, C. D., Santangelo, P. J., & Dahlman, J. E.
- Affiliations
- Georgia Institute of Technology (US)
- Corresponding author
- Dahlman, James E.
- ORCID
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2019-11-19
- Volume
- 32
- Issue
- 1
- Pages
- e1904905-e1904905
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- PMC
- PMC7029413
- OpenAlex
- W2990482336
- Cited by
- 126
- References
- 63
- Citations by year
- 2026: 18 · 2025: 12 · 2024: 16 · 2023: 27 · 2022: 29 · 2021: 12 · 2020: 11
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Advanced Materials (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Parkinson's Disease Foundation (PDF‐JFA‐1860)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- lipid nanoparticles, mRNA delivery, TLR4, innate immune activation, inflammation, Kupffer cells, endosomal escape, mRNA translation, PKR, endocytosis
- MeSH terms
- RAW 264.7 Cells, Animals, Endocytosis, Immunity, Innate, Lipids, Lipopolysaccharides, Macrophages, Mice, Transgenic, Endosomes, RNA, Messenger, Toll-Like Receptor 4, Mice, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
